Mass spectrometry quantifies target engagement for a KRASG12C inhibitor in FFPE tumor tissue

ConclusionsThis work illustrates the potential to expand mass spectrometry-based proteomics in preclinical and clinical oncology drug development through analysis of FFPE tumor biopsies.

Source: Clinical Proteomics - October 25, 2023 Category: Biochemistry Source Type: research